

DAY 1 – Friday, October 16, 2026

12:30 – 13:55

Lunch and welcome

Central chair & host: Dr. Marc Claessens, Urology, AZ Klina, Brasschaat, Belgium.

14:00 – 15:30

Prostate cancer

Robert and Albert: the story continues...

Patient case based interactive session

Chair: **Prof. Dr. Steven Joniau, Urology, UZ Leuven, Belgium.**

Discussants:

Prof. Dr. Alberto Bossi, Radiation Oncology, IGR, Paris, France.

Dr. Lorenzo Staelens, Radiation Oncology, AZ Delta, Roeselare, Belgium.

Dr. Sarah Buelens, Urology, AZ VUB, Jette, Belgium.

15:30 – 16:00

Coffee break

16:00 – 17:20

Bladder cancer: 2027 in preview

Chair: **Prof. Dr. Charles Van Praet, Urology, UZ Gent, Belgium.**

Panel: Dr. Anne-Catherine Claikens, Urology, Hageland Association, Belgium. + speakers and chair

Case presentation: TBD

What to expect:

From oncology: TBD

From surgery: **Dr. Yannic Raskin, Urology, ZOL, Belgium.**

From radiotherapy: **Prof. Dr. Valérie Fonteyne, Radiation Oncology, UZ Gent, Belgium.**

Case presentation continued: TBD.

Adjuvant treatments: What to expect from oncology: TBC

Adjuvant treatments: What to expect from radiation oncology: **Prof. Dr. Valérie Fonteyne, Radiation Oncology, UZ Gent, Belgium.**

17:20 – 17:30

Break

17:30 – 18:30

Satellite Symposium: Astellas

19:00

Networking reception and congress dinner

DAY 2 – Saturday, October 17, 2026

Central chair & host: Dr. Marc Claessens, Urology, AZ Klinka, Brasschaat, Belgium.

The patient with high-risk urological cancer: what to expect from 2027?

09:30 – 10:45

Kidney Cancer

Chair: Dr. Peter Schatteman, Urology, AZorg, Aalst, Belgium (TBC).

Panel: speakers and chair

Case presentation: de novo metastatic disease: TBC

Is there a role for cytoreductive nephrectomy? Prof. Dr. Karel Decaestecker, Urology, AZ Maria Middelaers Gent, Belgium.

Case presentation: recurrent oligometastatic disease: TBC.

The optimal systemic treatment combination: Prof. Dr. Benoit Beuselinck – Medical Oncology, UZ Leuven, Belgium.

Are there other options? Prof. Dr. Gert De Meerleer, Radiation Oncology, UZ Leuven, Belgium.

10:45 – 11:00

Coffee break

11:00 – 12:55

Prostate Cancer

Chair: Dr. Kato Rans, Radiation Oncology, AZ Turnhout, Belgium.

Panel: speakers and chair

Case presentation: high-risk prostate cancer: TBC

What's new from randomized controlled trials? Prof. Dr. Steven Joniau – Urology, UZ Leuven, Belgium.

Case presentation: de novo low-volume metastatic disease: TBC.

The optimal systemic treatment combination: Prof. Dr. Brieuc Sautois – Medical Oncology, CHU de Liège, Belgium.

Is there still a place for treatment of the primary? Prof. Dr. Alberto Bossi, Radiation Oncology, IGR, Paris, France.

Still place for new clinical studies? Dr. Alexander Giesen, Urology, RZ Tienen, Belgium.

What's new in metastatic castration refractory disease? Prof. Dr. Brieuc Sautois – Medical Oncology, CHU de Liège, Belgium.

12:55 – 13:00

Closing remarks